Business Context and Reporting Period
This Form 8-K Current Report was filed by Akebia Therapeutics, Inc. on February 18, 2021, covering events occurring on February 16, 2021. The filing addresses corporate governance changes, specifically the election of a new director and the resignation of an existing director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size from nine to ten members.
- New Director Election: LeAnne M. Zumwalt was elected as a Class III director, with a term expiring at the 2023 annual meeting. She was also appointed to the Audit Committee.
- Director Resignation: Maxine Gowen, Ph.D., notified the company of her resignation as a Class III director, effective June 6, 2021. The resignation is not due to any disagreement with the company.
Compensation and Governance Details
Ms. Zumwalt's compensation under the Non-Employee Director Compensation Program includes:
- Cash Retainers: $45,000 annually for Board service and $10,000 annually for Audit Committee service.
- Annual Equity Grants: 20,100 stock options and 13,700 restricted stock units.
- Initial Grant: On February 16, 2021, she received an initial grant of 80,200 options at an exercise price of $4.87 per share.
Investor Verification Checklist
- Verify the effective date of Maxine Gowen's resignation (June 6, 2021) and confirm no interim governance gaps.
- Review the total number of outstanding options and restricted stock units granted to Ms. Zumwalt to assess potential dilution.
- Confirm the composition of the Audit Committee following Ms. Zumwalt's appointment.
- Check subsequent filings for any changes to the Board size or composition prior to the 2023 annual meeting.